Gardent Pharmaceuticals Inc., Symbollon, Switch Pharma deal

SYMBA and GRDP mutually terminated a marketing agreement for SYMBA's IoGen molecular iodine to treat pain and tenderness associated with fibrocystic breast disease (see BioCentury, April 18, 2005). GRDP, formerly Bioaccelerate Holdings Inc., was responsible for development and commercialization expenses. ...